Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$1,705 Mln
P/E Ratio
--
P/B Ratio
0.6
Industry P/E
--
Debt to Equity
0.17
ROE
-0.51 %
ROCE
-36.48 %
Div. Yield
0 %
Book Value
44.35
EPS
-30.12
CFO
$2,983.48 Mln
EBITDA
$4,047.22 Mln
Net Profit
$2,165.07 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Quidel (QDEL)
| -43.50 | -30.32 | -39.90 | -37.54 | -39.01 | -25.52 | 0.23 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Quidel (QDEL)
| -39.30 | -13.97 | -24.86 | 139.44 | 53.69 | 12.55 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.10 | 10,391.68 | 14.66 | 12.69 | |
| 71.01 | 9,766.86 | 94.68 | 2.52 | |
| 152.15 | 8,196.06 | -- | -25.23 | |
| 277.35 | 10,728.90 | 770.42 | 1.2 |
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments... and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. Address: 9975 Summers Ridge Road, San Diego, CA, United States, 92121 Read more
Interim CEO, Executive VP & Chief Commercial Officer
Mr. Michael S. Iskra
Interim CEO, Executive VP & Chief Commercial Officer
Mr. Michael S. Iskra
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Quidel Corporation (QDEL) stood at $ 6,424 Mln as on 31-Dec-24
The share price of Quidel Corporation (QDEL) is $25.17 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Quidel Corporation (QDEL) has given a return of -39.01% in the last 3 years.
Quidel Corporation (QDEL) has a market capitalisation of $ 1,705 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Quidel Corporation (QDEL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Quidel Corporation (QDEL) and enter the required number of quantities and click on buy to purchase the shares of Quidel Corporation (QDEL).
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. Address: 9975 Summers Ridge Road, San Diego, CA, United States, 92121
The CEO & director of Mr. Michael S. Iskra. is Quidel Corporation (QDEL), and CFO & Sr. VP is Mr. Michael S. Iskra.
There is no promoter pledging in Quidel Corporation (QDEL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| Quidel Corporation (QDEL) | Ratios |
|---|---|
|
Return on equity(%)
|
-50.74
|
|
Operating margin(%)
|
-69.83
|
|
Net Margin(%)
|
-72.84
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Quidel Corporation (QDEL) was $0 Mln.
$-0.10
(
